Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2021
Event: Entry into a Material Definitive Agreement (Fourth Amended and Restated Credit and Security Agreement).
Key Financial Metrics
This filing details a refinancing transaction rather than periodic operating results. Key financial figures related to the debt facility include:
- Total Credit Facility Amount: $25.0 million (entirely drawn at closing).
- Converted Term Loan: Approximately $20,833,333.35 (rolled over from prior agreement).
- New 2021 Term Loan: Approximately $4,166,666.65.
- Interest Rate: LIBOR-based (minimum 1.00% floor) plus 6.75%.
- Repayment Terms: Interest-only payments monthly until May 1, 2024; principal amortization thereafter.
- Maturity Date: November 30, 2025 (automatically extends to April 1, 2026 if $37.5 million in 2026 Convertible Notes are fully converted).
Material Changes Versus Prior Period
The Company refinanced its existing secured term loan facility, replacing the Third Amended and Restated Credit and Security Agreement (dated December 21, 2018, as amended). Material changes include:
- Extension of Term: The facility maturity is extended to November 30, 2025, with a potential extension to April 1, 2026.
- Increased Principal: The total principal amount increased from approximately $20.8 million to $25.0 million through the addition of a new $4.17 million term loan.
- Security Interest: The Company granted a first-priority security interest in all assets, including intellectual property, to the Lenders.
- Covenants: New negative covenants restrict payments on the 2026 Convertible Notes except for conversions to equity and certain permitted expenses.
Guidance, Outlook, Risks, and Unusual Items
Prepayment and Exit Fees: The agreement imposes significant fees for early repayment or maturity:
- Prepayment Fees: 3.00% (within 1 year), 2.00% (years 1-2), and 1.00% (years 2-3) of outstanding principal prepaid.
- Exit Fee: 3.50% of the Total Credit Facility Amount ($25.0 million) payable at maturity, less any partial exit fees paid.
- Partial Exit Fee: 3.50% of outstanding principal prepaid.
Risks and Contingencies:
- Default Acceleration: Obligations are subject to acceleration upon events of default, including a material adverse change in the Company's business or a breach of the 2026 Convertible Notes.
- Default Interest: In the event of a default, the interest rate may increase by an additional 4.00%.
- Operational Restrictions: The agreement includes customary limitations on dispositions, mergers, incurring additional indebtedness, paying dividends, and making certain investments.
Financial Performance: The filing text does not provide revenue, profit, cash flow, or margin data for the reporting period.
Investor Verification Checklist
- Verify the status of the $37.5 million 2026 Convertible Notes to determine if the maturity extension to April 2026 is achievable.
- Review the impact of the 6.75% LIBOR spread plus floor on future interest expense compared to the prior facility.
- Assess the liquidity impact of the 3.50% exit fee payable at maturity.
- Confirm compliance with the new negative covenants restricting payments on the 2026 Convertible Notes.
- Monitor for any events of default that could trigger the 4.00% penalty interest rate or acceleration of debt.